Chonluten is a synthetic tripeptide composed of L-glutamyl-L-asparagyl-L-glycine (Glu-Asp-Gly) investigated in preclinical models for its role in bronchial tissue homeostasis, gene expression, and cellular signaling. Formulated exclusively for laboratory research use, Chonluten serves as an important short-chain peptide tool for evaluating epithelial responses in vitro.
Chonluten is a synthetic tripeptide composed of L-glutamyl-L-asparagyl-L-glycine (Glu-Asp-Gly) investigated in preclinical models for its role in bronchial tissue homeostasis, gene expression, and cellular signaling. Formulated exclusively for laboratory research use, Chonluten serves as an important short-chain peptide tool for evaluating epithelial responses in vitro.
Chonluten (Glu-Asp-Gly) is a low-molecular-weight synthetic bioregulator tripeptide derived from primary sequence motifs identified in bronchial mucosal tissues. Belonging to the class of short-chain signal peptides, its molecular architecture consists of three amino acids linked sequentially: L-glutamic acid, L-asparagine, and glycine. In biochemical literature, small peptide fragments of this class are studied for their potential to penetrate nuclear membranes and interact directly with specific genomic regions.
In cell culture and tissue explant models, researchers utilize Chonluten to observe localized protein synthesis dynamics and chromatin structure modifications. Because of its ultra-short peptide chain, it exhibits high stability under standardized laboratory conditions compared to larger protein constructs. Understanding its basic sequence dynamics provides foundational insight into how short peptide signals interact with nuclear histone proteins and nucleosome structures during transcriptional regulation.
Research interest in short-chain bioregulators stems from the hypothesis that specific amino acid motifs act as localized epigenetic modifiers. Studies published in structural biology journals indicate that tripeptides like Glu-Asp-Gly may selectively bind to DNA promoter regions, influencing gene expression without permanent genomic alteration. Scientists evaluating cellular signaling mechanisms frequently utilize this peptide to assess transcriptional activity in isolated cell lines.
The molecular formula of Chonluten is C11H17N3O8, featuring a peptide backbone optimized for chemical stability during analytical testing. The presence of acidic residue side chains (glutamic acid and asparagine) imparts specific ionic characteristics, allowing the compound to form electrostatic bonds with basic chromosomal proteins under controlled pH conditions.
Preclinical in vitro assays suggest that Chonluten interacts with double-stranded DNA via minor groove binding mechanisms. By occupying specific sites along the chromatin chain, the peptide is hypothesized to influence nucleosome unfolding and transcription factor access. Researchers studying non-coding RNA pathways and histone modification often include short-chain bioregulators in their experimental assays to map chromatin accessibility across primary respiratory cell lines.
Additionally, the simple glycine C-terminus grants conformational flexibility to the tripeptide, permitting structural adaptations when entering active binding pockets of nuclear proteins. This flexibility is a central subject of study in computer-aided molecular docking simulations and circular dichroism spectroscopy assays designed to model target-peptide interfaces.
In preclinical laboratory research, Chonluten has been widely examined in rodent models and cell culture preparations focused on respiratory epithelial mechanics. In vitro exposure of primary bronchial epithelial cells to synthetic Glu-Asp-Gly has demonstrated measurable shifts in the expression of structural cytokeratins and surfactant-associated proteins. These findings indicate a potential role in modulating cell differentiation pathways during tissue remodeling assays.
Experimental models evaluating environmental challenge factors—such as oxidative stress, thermal shock, or chemical exposure—frequently utilize Chonluten to monitor cellular repair rates. Laboratory observations note that organotypic cultures treated with the peptide maintain higher tight-junction integrity and reduced apoptosis rates compared to untreated control groups. Such data highlight the peptide's utility as a molecular probe for investigating mucosal barrier function.
Furthermore, animal models evaluating chronic inflammatory signaling in pulmonary tissue indicate that Glu-Asp-Gly administration correlates with altered cytokine profiles in bronchoalveolar lavage fluid. In particular, preclinical studies report down-regulation of pro-inflammatory markers such as IL-6 and TNF-alpha, alongside normalized transcription of endogenous antioxidant enzymes like superoxide dismutase (SOD) and catalase.
When designing comparative assays for tissue-specific bioregulators, researchers frequently group Chonluten alongside other short-chain peptide signals targeting distinct organ systems. Evaluating structural and functional differences across these compounds helps clarify tissue tropism and target receptor selectivity in vitro.
For instance, while Chonluten targets bronchial epithelial dynamics, Bronchogen (Ala-Glu-Asp-Leu) represents a tetrapeptide variant similarly studied in pulmonary research models to evaluate synergistic mucosal signaling. In vascular endothelial studies, investigators contrast these respiratory peptides with Vesugen (Lys-Glu-Asp), a tripeptide tailored for vascular cell matrix and vessel wall dynamic assays. Similarly, tissue remodeling research involving connective matrix systems relies on Cartalax (Ala-Glu-Asp) for cartilaginous and chondrocyte cell lines.
Comparing these sequence variations allows structural biologists to determine how minor alterations—such as replacing glycine with alanine or adding a leucine residue—shift DNA-binding affinities and target cell specificity. Research facilities often procure comprehensive panels from the PX1 Research all peptides catalog to execute systematic, multi-compound comparative profiling.
To ensure precise molarity and preserve peptide integrity during laboratory testing, strict handling and reconstitution procedures must be followed. Chonluten is supplied as a lyophilized (freeze-dried) sterile powder in sealed glass vials, requiring appropriate liquid reconstitution prior to in vitro application.
Reconstitution should be conducted within a certified laminar flow hood using sterile laboratory-grade solvents. For standard cell culture assays, sterile bacteriostatic water or phosphate-buffered saline (PBS, pH 7.4) is recommended depending on the final target concentration and assay requirements. The solvent should be added gently down the inner glass wall of the vial, followed by gentle swirling; high-shear vortexing or vigorous agitation must be avoided to prevent mechanical degradation of the peptide chain.
Once fully dissolved, working aliquots should be prepared immediately to minimize freeze-thaw cycles. Lyophilized vials should be stored at -20°C prior to preparation. Once reconstituted, solution aliquots should be kept at 2°C to 8°C for short-term use (up to 7 days) or stored at -80°C for long-term experimental consistency. Experimental concentrations typically range from 0.01 ng/mL to 100 ng/mL depending on the specific primary cell line or organoid model evaluated.
The reliability of preclinical peptide research depends entirely on the analytical purity and lot-to-lot consistency of the subject compound. PX1 Research enforces rigorous quality control protocols to guarantee that every batch of Chonluten meets exacting chemical standards before distribution to scientific laboratories.
Analytical verification begins with High-Performance Liquid Chromatography (RP-HPLC) to confirm peptide purity levels exceeding 98.0%. In tandem, Electrospray Ionization Mass Spectrometry (ESI-MS) is utilized to verify precise molecular weight and rule out truncated sequence fragments, deletion peptides, or counterion impurities. Each production lot is assigned a unique Certificate of Analysis (COA) documenting exact chromatographic profiles and structural validation data.
In addition to purity metrics, research compounds must be screened for biological contaminants that could skew cell culture data. Endotoxin levels are quantitatively measured using Limulus Amebocyte Lysate (LAL) testing, verifying endotoxin limits strictly under 0.05 EU/mg. All PX1 Research peptides are USA-manufactured in ISO 17025 accredited, GMP-compliant facilities, ensuring full traceability and zero batch variability for high-throughput institutional studies.
Integrating Chonluten into cell culture workflows requires careful calibration of experimental controls, vehicle reagents, and sampling intervals. Researchers evaluating gene expression should establish baseline non-treated controls alongside solvent-vehicle controls to isolate true peptide-induced transcriptomic shifts.
Common downstream readouts include Quantitative Reverse Transcription PCR (RT-qPCR) to measure changes in surfactant protein gene transcripts (e.g., SFTPA1, SFTPB) and enzyme-linked immunosorbent assays (ELISA) to monitor secretome protein secretion. Time-course assays spanning 12, 24, 48, and 72 hours are recommended to capture both early-phase chromatin remodeling events and late-stage protein synthesis responses.
For laboratories establishing automated high-throughput screening, bulk procurement programs available through PX1 Research's wholesale portal provide single-lot batch consistency required to eliminate inter-assay variance across extended research timelines. Institutional access ensures uninterrupted supply chains backed by same-day shipping fulfillment from centralized California and Arizona distribution hubs.
What is Chonluten and what is its chemical sequence?
Chonluten is a synthetic bioregulator tripeptide composed of L-glutamyl-L-asparagyl-L-glycine (Glu-Asp-Gly). It is synthesized for laboratory and in vitro research focused on bronchial tissue regulation and chromatin interactions.
What primary research applications involve Chonluten?
Chonluten is studied primarily in respiratory cell culture models, organotypic epithelial cultures, and rodent assays to investigate gene expression, cytokeratin synthesis, cell differentiation, and inflammatory cytokine response.
How is Chonluten analytical purity verified?
PX1 Research verifies Chonluten purity using Reverse-Phase High-Performance Liquid Chromatography (RP-HPLC) to ensure >98% purity, paired with Mass Spectrometry (MS) for sequence identity verification. Every lot includes a third-party Certificate of Analysis (COA).
What are the storage requirements for lyophilized Chonluten?
Lyophilized Chonluten vials should be stored at -20°C in a dry environment protected from light. Upon reconstitution with sterile solvent, aliquots should be stored at -80°C for long-term preservation.
What solvent should be used for reconstituting Chonluten in cell culture assays?
Reconstitution is typically performed using sterile bacteriostatic water, sterile normal saline (0.9% NaCl), or phosphate-buffered saline (PBS, pH 7.4) under laminar airflow hood conditions.
What is the endotoxin limit for PX1 Research Chonluten?
All research-grade Chonluten supplied by PX1 Research undergoes LAL assay testing to confirm endotoxin levels are below 0.05 EU/mg, preventing background inflammatory activation in cell assays.
How does Chonluten differ from Bronchogen?
Chonluten is a tripeptide (Glu-Asp-Gly) whereas Bronchogen is a tetrapeptide (Ala-Glu-Asp-Leu). While both are investigated for bronchial tissue research, their differing amino acid sequences result in distinct DNA binding dynamics and target signaling profiles.
Is Chonluten approved for human therapeutic use or clinical administration?
No. Chonluten is strictly a research chemical designated for in vitro, biochemical, and animal laboratory experimentation. It is not approved for clinical human or veterinary consumption.
All products are sold strictly for laboratory and research use only. Not for human or veterinary use, diagnosis, treatment or consumption. Statements have not been evaluated by the FDA.